October 27, 2026Stocks·Neutral·m&a

Teva Pharmaceuticals acquires BioXcel Therapeutics' assets for $57.5M upfront

Teva Pharmaceuticals International GmbH is acquiring BioXcel Therapeutics' assets for a $57.5 million upfront payment.

Detected & updated continuously · Source: Nebula

Story subjects

BioXcel Therapeutics, Inc.Teva Pharmaceuticals International GmbH

Track sentiment and mindshare across stocks and crypto in Nebula.